DongGuan Winnerway Industry Zone (000573.SZ) plans to acquire 100% equity of Shenzhen Jinwangda Electromechanical Co., Ltd. for RMB550 million.
DongGuan Winnerway Industry Zone (000573.SZ) announced that on November 11, 2026, the company signed a conditional equity transfer agreement with Xu Zhaowang and Anyi Tuohuangzhe Enterprise Management Partnership (Limited Partnership) regarding Shenzhen Jinwangda Electromechanical Co., Ltd. The company plans to acquire 100% equity of Shenzhen Jinwangda Electromechanical Co., Ltd. in cash, with a transaction price of RMB550 million.
DongGuan Winnerway Industry Zone (000573.SZ) announced that on November 11, 2026, the company signed a conditional equity transfer agreement with Xu Zhaowang and Anyi Tuohuangzhe Enterprise Management Partnership (Limited Partnership) regarding Shenzhen Jinwangda Electromechanical Co., Ltd. The company plans to acquire 100% equity of Shenzhen Jinwangda Electromechanical Co., Ltd. in cash, with a transaction price of RMB550 million.
This transaction includes performance commitments, compensation arrangements, and performance incentives. The performance commitment parties have committed that the target company's net profit attributable to the parent company will be no less than RMB36 million in 2026, no less than RMB41.5 million in 2027, no less than RMB47.5 million in 2028, and no less than RMB55 million in 2029.
The company plans to enter ShenZhen New Industries Biomedical Engineering through merger and acquisition. Centering on the target company's core business, the company will consolidate the foundation of its new main business, steadily expand the scale of the new main business through parallel external expansion and organic development, and achieve secondary growth. This transaction is a key measure for the company to implement its industrial transformation strategy, helping the company break away from dependence on traditional industry cycles, upgrade its business structure from being primarily focused on traditional industries to a dual-wheel-driven pattern of existing industries + new tracks, and achieve long-term sustainable development.
Related Articles

US Stock Market Move | Nasdaq futures surge 1.91%; most star tech stocks rise in premarket trading.

One Micro Technology (02065) Hong Kong public offering received 13.95 times subscription; global offering raised net proceeds of approximately HK$655.9 million

Monotherapy for glucose lowering surpasses tirzepatide, and in head-to-head combination therapy it is superior to semaglutide: Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) BGM0504 competes for the global glucose-lowering benchmark.
US Stock Market Move | Nasdaq futures surge 1.91%; most star tech stocks rise in premarket trading.

One Micro Technology (02065) Hong Kong public offering received 13.95 times subscription; global offering raised net proceeds of approximately HK$655.9 million

Monotherapy for glucose lowering surpasses tirzepatide, and in head-to-head combination therapy it is superior to semaglutide: Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) BGM0504 competes for the global glucose-lowering benchmark.






